0001140361-23-024714.txt : 20230515 0001140361-23-024714.hdr.sgml : 20230515 20230515161957 ACCESSION NUMBER: 0001140361-23-024714 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230515 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230515 DATE AS OF CHANGE: 20230515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: STRATA Skin Sciences, Inc. CENTRAL INDEX KEY: 0001051514 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 133986004 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51481 FILM NUMBER: 23922784 BUSINESS ADDRESS: STREET 1: 5 WALNUT GROVE DRIVE STREET 2: SUITE 140 CITY: HORSHAM STATE: PA ZIP: 19044 BUSINESS PHONE: 215-619-3200 MAIL ADDRESS: STREET 1: 5 WALNUT GROVE DRIVE STREET 2: SUITE 140 CITY: HORSHAM STATE: PA ZIP: 19044 FORMER COMPANY: FORMER CONFORMED NAME: MELA SCIENCES, INC. /NY DATE OF NAME CHANGE: 20100504 FORMER COMPANY: FORMER CONFORMED NAME: ELECTRO OPTICAL SCIENCES INC /NY DATE OF NAME CHANGE: 19971216 8-K 1 brhc20052965_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 15, 2023

graphic
STRATA Skin Sciences, Inc.
(Exact Name of Registrant Specified in Charter)

Delaware
 000-51481
13-3986004
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania
19044
(Address of Principal Executive Offices)
(Zip Code)

Registrant's telephone number, including area code:   215-619-3200

 (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
 SSKN
The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.
Results of Operations and Financial Condition.

On May 15, 2023, STRATA Skin Sciences, Inc. (the “Company”) issued a press release announcing its results of operations for the first fiscal quarter ended March 31, 2023. The full text of such press release is furnished as Exhibit 99.1 to this report.

The information set forth under this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 7.01.
Regulation FD Disclosure.

On May 15, 2023, STRATA Skin Sciences, Inc. (the “Company”) issued a press release announcing its results of operations for the first fiscal quarter ended March 31, 2023. The full text of such press release is furnished as Exhibit 99.1 to this report.

The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01.
Financial Statements and Exhibits.
 
(d)
Exhibits.

The following press release is furnished as an exhibit to this Current Report on Form 8-K pursuant to Item 2.02 and shall not be deemed to be “filed”:

 
Press Release dated May 15, 2023 issued by STRATA Skin Sciences, Inc.
 
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
STRATA SKIN SCIENCES, INC.
  
       
Date: May 15, 2023
By:
/s/ Christopher Lesovitz
  
   
Christopher Lesovitz
  
   
Chief Financial Officer
  


EX-99.1 2 brhc20052965_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1          Press Release dated May 15, 2023 issued by STRATA Skin Sciences, Inc.

STRATA Skin Sciences Reports First Quarter 2023 Revenue
 
Achieved revenue of $7.6 million for the first quarter 2023
 
Company to host conference call and webcast today, May 15, 2023, at 4:30 PM ET

HORSHAM, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the first quarter ended March 31, 2023.

First Quarter 2023 and Recent Business Highlights:

 ●
Revenue in the first quarter of 2023 was $7.6, compared to $7.0 million for the first quarter of 2022

●
Officially launched TheraClear®X device in January 2023

●
58 TheraClear devices in the U.S. as of March 31, 2023

●
Sold over 3,000 TheraClear treatments in the first quarter

●
Signed exclusive distribution agreement with Spectra Medical Pvt Ltd. for India

“The first quarter of 2023 has been filled with commercial successes for STRATA, especially with the ramp-up of TheraClearX,” stated Bob Moccia, Chief Executive Officer of STRATA Skin Sciences. “In addition to officially launching TheraClear this January, we also reached a milestone of selling 3,000 TheraClear treatments during the quarter.”

Mr. Moccia further commented, “As part of our strategic priorities, we plan to continue placing TheraClear devices throughout the United States and abroad. In the first quarter alone, we placed 44 TheraClear devices, now totaling 58 in the United States. We recently announced an exclusive distribution agreement with Spectra Medical which will be the first supplier of excimer laser solutions for phototherapy treatments in India. We will continue this momentum into the remainder of the year as we deliver on our plan and ultimately grow the topline.”

First Quarter Financial Results
Revenues for the first quarter of 2023 were $7.6 million, as compared to revenues of $7.0 million for the first quarter of 2022. Global recurring revenues for the first quarter of 2023 were $5.2 million, as compared to global recurring revenues of $5.1 million for the first quarter of 2022. Equipment revenues were $2.4 million for the first quarter of 2023, as compared to $2.0 million for the first quarter of 2022.

Gross profit for the first quarter of 2023 was $4.4 million, or 58.0% of revenues, as compared to $4.1 million, or 59% of revenues, for the first quarter of 2022.

-1-
Selling and marketing costs for the first quarter of 2023 were $3.7 million, as compared to $3.6 million for the first quarter of 2022. General and administrative costs for the first quarter of 2023 were $2.9 million, as compared to $2.7 million for the first quarter of 2022.

Other expense for the first quarter of 2023 was $0.3 million, as compared to $0.2 million for the first quarter of 2022.

Net loss for the first quarter of 2023 was $2.8 million, or a loss of $0.08 per basic and diluted common share, as compared to the net loss for the first quarter of 2022 of $2.5 million, or a net loss of $0.07 per basic and diluted common share.

Financial Outlook
STRATA continues to expect full year 2023 revenue to range from $38.0 million to $40.0 million.

Webcast and Conference Call Information
STRATA management will host a conference call today, beginning at 4:30 PM ET. The conference call will be concurrently webcast. The link to the webcast is available here: STRATA Skin Sciences Earnings Webcast and will be archived for future reference. To listen to the conference call, please dial 1-877-269-7756 (US/Canada), 1-201-689-7817 (International), and use the conference ID number 13738266.

Reconciliation of Non-GAAP Measures
To supplement the Company’s consolidated financial statements, prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), the Company provides certain non-GAAP measures of financial performance, including non-GAAP adjusted EBITDA and Gross Domestic Recurring Billings.

The Company’s reference to these non-GAAP measures should be considered in addition to results prepared under current accounting standards but is not a substitute for, nor superior to, GAAP results. These non-GAAP measures are provided to enhance investors' overall understanding of our current financial performance and to provide further information for comparative purposes.

Specifically, the Company believes the non-GAAP measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of the Company’s core operating results and business outlook. In addition, the Company believes non-GAAP measures enhance the comparability of results against prior periods. Reconciliation of the GAAP measures of net loss to non-GAAP measures included in this press release is as follows (in thousands) (unaudited):

-2-
   
For the Three Months Ended March 31,
  
   
2023
    
2022
  
Net loss
  
$
(2,835
)
  
$
(2,502
)
                 
Adjustments:
                
Depreciation and amortization
    
1,397
      
1,321
  
Amortization of operating lease right-of-use asset
    
105
      
89
  
Loss on disposal of property and equipment
    
—
      
17
  
Interest expense, net
    
249
      
199
  
Non-GAAP EBITDA
    
(1,084
)
    
(876
)
Stock-based compensation expense
    
325
      
368
  
Non-GAAP adjusted EBITDA
  
$
(759
)
  
$
(508
)

XTRAC Gross Domestic Recurring Billings
XTRAC gross domestic recurring billings represent the amount invoiced to partner clinics when treatment codes are sold to the physician. It does not include normal GAAP adjustments, which are deferred revenue from prior quarters recorded as revenue in the current quarter, the deferral of revenue from the current quarter recorded as revenue in future quarters, adjustments for co-pay and other discounts. This excludes international recurring revenues.

The following is a reconciliation of non-GAAP XTRAC gross domestic billings to domestic recorded revenue for the first quarter 2023 and 2022 (in thousands):

   
Three Months Ended March 31,
  
   
2023
    
2022
  
Gross domestic recurring billings
  
$
4,735
    
$
4,999
  
Co-Pay adjustments
    
(83
)
    
(170
)
Other discounts
    
(28
)
    
(37
)
Deferred revenue from prior quarters
    
2,170
      
1,867
  
Deferral of revenue to future quarters
    
(2,025
)
    
(1,970
)
GAAP Recorded domestic revenue
  
$
4,769
    
$
4,689
  

About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing and marketing innovative products for the in-office treatment of various dermatologic conditions such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.

STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

-3-
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell an acne treatment device and to integrate that device into its product offerings, the Company’s ability to develop, launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to dermatologist marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from the coronavirus, fiscal, and political factors, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general,  as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.

Investor Contact:
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
sskn@cg.capital
 
-4-
STRATA Skin Sciences, Inc. and Subsidiary
1.  Condensed Consolidated Balance Sheets
2. (in thousands, except share and per share amounts)

   
March 31, 2023
    
December 31,
2022
  
   
(unaudited)
        
Assets
            
Current assets:
            
Cash and cash equivalents
  
$
2,825
    
$
5,434
  
Restricted cash
    
1,361
      
1,361
  
Accounts receivable, net of allowance for doubtful
accounts of $242 and $382 at March 31, 2023 and
December 31, 2022, respectively
    
3,940
      
4,471
  
Inventories
    
5,695
      
5,547
  
Prepaid expenses and other current assets
    
691
      
691
  
Total current assets
    
14,512
      
17,504
  
Property and equipment, net
    
8,182
      
7,498
  
Operating lease right-of-use assets
    
870
      
975
  
Intangible assets, net
    
16,674
      
17,394
  
Goodwill
    
8,803
      
8,803
  
Other assets
    
82
      
98
  
Total assets
  
$
49,123
    
$
52,272
  
                 
Liabilities and Stockholders’ Equity
                
Current liabilities:
                
Accounts payable
  
$
3,099
    
$
3,425
  
Accrued expenses and other current liabilities
    
6,549
      
6,555
  
Deferred revenues
    
2,548
      
2,778
  
Current portion of operating lease liabilities
    
381
      
355
  
Current portion of contingent consideration
    
481
      
313
  
Total current liabilities
    
13,058
      
13,426
  
Long-term debt, net
    
7,517
      
7,476
  
Deferred revenues and other liabilities
    
305
      
314
  
Deferred tax liability
    
306
      
306
  
Operating lease liabilities, net of current portion
    
489
      
610
  
Contingent consideration, net of current portion
    
8,127
      
8,309
  
Total liabilities
    
29,802
      
30,441
  
                 
Stockholders’ equity:
                
Series C convertible preferred stock, $0.10 par value; 10,000,000 shares authorized; no shares issued and outstanding
    
—
      
—
  
Common stock, $0.001 par value; 150,000,000 shares authorized; 34,881,453 and 34,723,046 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively
    
35
      
35
  
Additional paid-in capital
    
249,349
      
249,024
  
Accumulated deficit
    
(230,063
)
    
(227,228
)
Total stockholders’ equity
    
19,321
      
21, 831
  
Total liabilities and stockholders’ equity
  
$
49,123
    
$
52,272
  

-5-
STRATA Skin Sciences, Inc. and Subsidiary
Condensed Consolidated Statement of Operations
(in thousands, except share and per share amounts)
(unaudited)

   
Three Months Ended March 31,
  
   
2023
    
2022
  
Revenues, net
  
$
7,567
    
$
7,041
  
Cost of revenues
    
3,179
      
2,913
  
Gross profit
    
4,388
      
4,128
  
                 
Operating expenses:
                
Engineering and product development
    
315
      
163
  
Selling and marketing
    
3,742
      
3,616
  
General and administrative
    
2,917
      
2,652
  
     
6,974
      
6,431
  
                 
Loss from operations
    
(2,586
)
    
(2,303
)
                 
Other (expense) income:
                
Interest expense
    
(286
)
    
(199
)
Interest income
    
37
      
—
  
     
(249
)
    
(199
)
Net loss
  
$
(2,835
)
  
$
(2,502
)
Net loss per share of common stock, basic and diluted
  
$
(0.08
)
  
$
(0.07
)
Weighted average shares of common stock outstanding, basic and diluted
    
34,862,092
      
34,679,246
  

-6-
STRATA Skin Sciences, Inc. and Subsidiary
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
   
For the Three Months Ended March 31,
  
   
2023
    
2022
  
Cash flows from operating activities:
            
Net loss
  
$
(2,835
)
  
$
(2,502
)
Adjustments to reconcile net loss to net cash used in operating activities:
                
Depreciation and amortization
    
1,397
      
1,321
  
Amortization of operating lease right-of-use assets
    
105
      
89
  
Amortization of deferred financing costs and debt discount
    
41
      
37
  
(Recoveries of) provision for doubtful accounts
    
(95
)
    
13
  
Stock-based compensation expense
    
325
      
368
  
Loss on disposal of property and equipment
    
—
      
17
  
Changes in operating assets and liabilities:
                
Accounts receivable
    
626
      
448
  
Inventories
    
(103
)
    
(1,198
)
Prepaid expenses and other assets
    
16
      
85
  
Accounts payable
    
(326
)
    
1,148
  
Accrued expenses and other liabilities
    
(12
)
    
175
  
Deferred revenues
    
(247
)
    
(257
)
Operating lease liabilities
    
(95
)
    
(97
)
Net cash used in operating activities
    
(1,203
)
    
(353
)
Cash flows from investing activities:
                
Purchase of property and equipment
    
(1,406
)
    
(679
)
Cash paid in connection with TheraClear asset acquisition
    
—
      
(631
)
Net cash used in investing activities
    
(1,406
)
    
(1,310
)
Net decrease in cash, cash equivalents and restricted cash
    
(2,609
)
    
(1,663
)
Cash, cash equivalents and restricted cash, beginning of period
    
6,795
      
12,586
  
Cash, cash equivalents and restricted cash, end of period
  
$
4,186
    
$
10,923
  
Cash and cash equivalents
  
$
2,825
    
$
10,923
  
Restricted cash
    
1,361
      
—
  
   
$
4,186
    
$
10,923
  
Supplemental disclosure of cash flow information:
                
Cash paid for interest
  
$
241
    
$
160
  
Supplemental disclosure of non-cash operating, investing and financing activities:
                
Inventories acquired in connection with TheraClear asset acquisition
  
$
—
    
$
71
  
Intangible assets acquired in connection with TheraClear asset acquisition
  
$
—
    
$
10,182
  
Contingent consideration issued in connection with TheraClear asset acquisition
  
$
—
    
$
9,122
  
Common stock issued in connection with TheraClear asset acquisition
  
$
—
    
$
500
  
Transfer of property and equipment to inventories
  
$
45
    
$
—
  
Accrued payment of contingent consideration
  
$
14
    
$
—
  


-7-
EX-101.SCH 3 sskn-20230515.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 sskn-20230515_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 sskn-20230515_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image00001.jpg begin 644 image00001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# 8$!08%! 8&!08'!P8("A *"@D) M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_ MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P 1" O )0# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#V[Q%XWU#_ M (2>?PUX-T9=8UBVC26]EGN/(M;)7Y02/@DL1R%49QS5634OBCIZ&XNM \+Z MI$HR;;3]0EBF/^Z94VD_4BJFKZ'XF\)^.-8\4>$K[#65A.HZ6\PAG62-= MJR0NWRGY>JG'/0^ENT^+WAQ+F.U\21:GX8O'.U8]:M&@1C[2\QD>^Z@#I_!/ MBFP\7Z&NI:XMKA-DMM,AP\;KV8'^E9&O:GX\@U:XCT3PYHMWIRD> M3//J;1.XP,Y41G'.1UKI]*LM.M4GGTJ"UB2]D-U+);JH$[L!F0D?>) '/?BK MU 'F,'BKX@3ZAA!1<#&>J/]K?$S_H5?#G_@XD_^ M,U0^.C!9OAXS$!1XML223@#B2O2?MEM_S\0_]]B@#AM)\?7UMX@LM#\<: ^@ MWM^QCL;F.Y%S:73CG8) 4<]E8#/:O0*\C^+^JV/B:\T#PAH,T5_KLFJ6UX_ MV=@_V"&%P[S.1PG'R@'!.[BO7* "O,K#XJQW7Q';0?[-9-#>ZDTRWUCS/DEO MHT#O#MQQP2 <\LN!6S\6O$MQX<\)L-)'F:]J)L]B7SGV8B@#T=L[3MY..*\\_MCXG?] M"EX>_P#!R_\ \9K;^&?BD>+_ ?9:G+'Y%^NZWOK6^]H_-@UUG780(K6Y,Z%,#!W%5YSGC':N,_9Y_P"2='_L)WW_ *4R5Z70!QOQ,\8S M^$]/L(])TTZOKNI7'V>QT]9-AE(!9V)YPJJ"2?<>M:_@KQ':>+?"VFZYI^1! M>1!RA.3&_1D/NK J?I7$> #_ ,)MX_U?QO)\^E6._2-$SRK*I_?W _WG&T'^ MZI%'AT_\(/\ %B_\/O\ )H?B??J>F_W8KM1_I$(_WAB0#IU% 'J5%%% '"-\ M0K;2?'&H>'_%H@T:,[)-*O9WVPWL97YAO/RAU;C;G/(Q6YKFN>&!I,QUS4M' M.FNI\P74T9C9?0AC@UJZGIUEJMHUKJ=G;7EJWWH;B)9$/U5@17.V?PV\$V=T M+BV\)Z%',IRKBQCRI]1QQ^% '+?L^QLNBZ_)IZ7$7A6;599-#28,,6Q R4#< MB,MDJ#[UZK0H"J H X ':B@#R_P9_R7KXC_ /7IIG_HMZ]0JO%96L5Y/=Q6 MT"74X599EC >0+]T,W4X[9Z58H \G_:#L[;4;?P'8W\,<]I<^*;.&:*09616 M60%2/0UO?\*A^'__ $*6D?\ ?@5V=W96MX8#=VT$Y@D$T7FQA_+D'1UST89. M".:GH \:\,6EK\'_ !E)HTL$,/A+Q!<;M.O@@#6MR>MM*_4J>J$^XYZCV6JV MH6%IJ5JUMJ-K;W=LQ!:*>,2(2#D<$8ZU9P ,#ITH \J\-?\ %=_%?4/$;'S- M#\,[],TSNLMTP_TB8?080'H>37JM5["QM-.M5MM/M8+6W4DK%!&$0$G)P!QR M>:L4 >52'_A OC"LA/E^'O&1"-V2#4D''T\U!CU++7JM5[ZQM+^.-+ZU@N4C MD65%FC#A77HPST([&K% 'FG[//\ R3H_]A.^_P#2F2K'QGUR[MM%L_#>A2[? M$/B2;^S[0CK#&1^^F]<(F>1T)%=Y96=M8P>38VT-M#N+[(8PB[BR6L#WD*E(YVC!D13U ;J >^* *OAO1;/P[H&GZ/ID?EV=E"L,8[D M =3[GJ3ZDUSOQ:\,W'B3PDYTEO+U[395U'3)1U6XCY5?HPRI[?-7:44 <_X! M\3VWC'PCINMV@V"YC_>Q'K#*.'C/NK BBMBRL;2Q21;*U@MEDD:5Q#&$#N>K M''4GN:* +%8_B:?4+>T@.F(S%I0)C&JO*L>TDE%8@,<[?PR0">*V*J:EIUKJ M4*QWD7F*C;T(8JR-ZJP((."1D'N: ,(ZW/#X/UC4%NH[BXL8YF#/;M$R%$W! M9(SR&'?&,C!'6I]!UJ;6=6O J&TM;8 +;SQE9Y0W*RD'[J'! '4X.<$;:TH- M'L(=.FL4MU^RS[O-5B6,FX8)8DY)(XR35A[.W>]BO&B4W,2-&DG\05L9'TX' M'M0!@WVLWD?A77KZ(Q+=6;7*PED)4;"0I89YZ#/(S[4RU\0W,NLZ;IMQ%'!> MF22.\AZ\",LKQGNC8X/U!P0:WGTZT>SN+5[=#;W!GXUR6@ZIJ;:C:P:Q.8;B96WVTEK MMC9@N?W$JDA@,="2Q'.!@UUO7K678^'],L;E)[6UV/&"(@79EBSUV*3A../E M XXH SX9]5U>ZU$V5]#8Q6EPULD9@$I9E ):3)& <\ 8.,'//%Z[OKB!M#7, M+-=W BF*9*D>3(_RGTR@_"EU#P_I>H7+3W5J&E=0LA5V3S0.@<*0''LV:O&S MMR+8>3&%MFW0@# C.TKP.WRL1^- ',ZAJ>HOXFN[&">ZA@A2';Y%CYPR^JAL9Q]<#\J ,*T\ M1I/INO:E#MNK.RS)!Y0P9$%NDA'URS#VZ=JET]-9 L[NXU2QFCFVF6%8=L>& M''E/G.>F"Z(3M0_P"Z!0!DZIJ>H'Q/ M<"@ T&[-]I-O<-<0W+,"#+"A16()!^4\J>,$'HN:FH **** /__9 end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 15, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 15, 2023
Entity File Number 000-51481
Entity Registrant Name STRATA Skin Sciences, Inc.
Entity Central Index Key 0001051514
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 13-3986004
Entity Address, Address Line One 5 Walnut Grove Drive
Entity Address, Address Line Two Suite 140
Entity Address, City or Town Horsham
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19044
City Area Code 215
Local Phone Number 619-3200
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol SSKN
Security Exchange Name NYSE
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 8 brhc20052965_8k_htm.xml IDEA: XBRL DOCUMENT 0001051514 2023-05-15 2023-05-15 false 0001051514 NYSE 8-K 2023-05-15 STRATA Skin Sciences, Inc. DE 000-51481 13-3986004 5 Walnut Grove Drive Suite 140 Horsham PA 19044 215 619-3200 false false false false Common Stock, $0.001 par value per share SSKN false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://strataskinsciences.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - brhc20052965_8k.htm 11 brhc20052965_8k.htm brhc20052965_ex99-1.htm sskn-20230515.xsd sskn-20230515_lab.xml sskn-20230515_pre.xml image00001.jpg http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc20052965_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "brhc20052965_8k.htm" ] }, "labelLink": { "local": [ "sskn-20230515_lab.xml" ] }, "presentationLink": { "local": [ "sskn-20230515_pre.xml" ] }, "schema": { "local": [ "sskn-20230515.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sskn", "nsuri": "http://strataskinsciences.com/20230515", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc20052965_8k.htm", "contextRef": "c20230515to20230515", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://strataskinsciences.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc20052965_8k.htm", "contextRef": "c20230515to20230515", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001140361-23-024714-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-23-024714-xbrl.zip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